Eidos therapeutics, inc. (EIDX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash Flows From Operating Activities:
Net loss

-22,824

-18,980

6,931

-14,053

-11,733

-9,854

-10,614

-11,381

-8,876

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

27

24

20

18

15

16

16

14

10

Stock-based compensation expense

1,927

1,648

1,595

1,166

964

825

694

619

388

Amortization of debt discount and issuance costs

204

-

-

-

-

-

-

-

-

Accrued interest on Convertible Promissory Notes payable

-

-

-

-

-

0

0

0

48

Change in fair value of derivative liability

62

-

-

-

-

0

0

0

100

Change in fair value of redeemable convertible preferred stock warrant liability

-

-

-

-

-

0

0

-2,665

37

Amortization of debt discount

-

-

-

-

-

0

0

0

963

Loss on disposal of asset

-

4

-56

-9

2

-

-

-

-

Changes in assets and liabilities:
Related party receivable

40

2

-114

125

38

5

8

-55

9

Prepaid expenses and other current assets

-726

-725

1,475

1,768

371

-1,459

1,003

1,621

140

Other assets

81

254

2,835

900

1,719

770

-6

-753

741

Accounts payable

821

-416

1,725

-1,370

1,256

-462

695

55

1,102

Accrued expenses and other liabilities

418

685

4,899

1,062

1,369

-862

1,632

-900

1,546

Related party payable

7

-56

28

-63

151

50

-325

204

-45

Net cash used in operating activities

-18,877

-16,505

10,989

-16,024

-10,108

-9,596

-8,907

-8,907

-5,891

Cash Flows From Investing Activities:
Purchases of property and equipment

51

-

-

-

-

6

15

15

114

Net cash used in investing activities

-51

-

-

-

-

-6

-15

-15

-114

Cash Flows From Financing Activities:
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

0

0

48,000

15,875

Proceeds from issuance of Convertible Promissory Notes payable

-

-

-

-

-

0

0

0

10,000

Proceeds from issuance of common stock upon exercise of stock options and restricted stock

192

-

-

-

25

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

187

Proceeds from the issuance of common stock in at-the-market offering

-

-

-

-

-

-

-

0

89

Net cash provided by financing activities

24,286

41,920

23,545

395

25

181

-1,199

160,342

25,777

Net increase (decrease) in cash and cash equivalents

5,358

25,335

34,422

-15,664

-10,083

-9,421

-10,121

151,420

19,772

Other supplemental information
Interest paid

518

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash activities:
Lease liability arising from the right of use asset

-

0

4,097

-129

1,187

-

-

-

-

Vesting of restricted stock and early exercised options

36

37

37

37

38

35

101

16

18

Conversion of Convertible Promissory Notes payable and accrued interest into redeemable convertible preferred stock

-

-

-

-

-

0

0

0

14,354

Open Market Sale Agreement
Proceeds from the issuance of common stock in at-the-market offering

24,100

-

-

-

-

-

-

-

-